Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of EUR 128.53 billion. The enterprise value is 142.99 billion.

Market Cap	128.53B
Enterprise Value	142.99B

Important Dates

The next estimated earnings date is Thursday, April 24, 2025.

Earnings Date	Apr 24, 2025
Ex-Dividend Date	Mar 14, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.24%
Shares Change (QoQ)	+0.40%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 277.21.

PE Ratio	277.21
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.37, with an EV/FCF ratio of 14.37.

EV / Earnings	308.42
EV / Sales	5.39
EV / EBITDA	11.37
EV / EBIT	14.49
EV / FCF	14.37

Financial Position

The company has a current ratio of 1.60, with a Debt / Equity ratio of 1.42.

Current Ratio	1.60
Quick Ratio	1.33
Debt / Equity	1.42
Debt / EBITDA	2.01
Debt / FCF	2.65
Interest Coverage	10.94

Financial Efficiency

Return on equity (ROE) is 2.29% and return on invested capital (ROIC) is 14.07%.

Return on Equity (ROE)	2.29%
Return on Assets (ROA)	11.03%
Return on Invested Capital (ROIC)	14.07%
Return on Capital Employed (ROCE)	22.74%
Revenue Per Employee	1.58M
Profits Per Employee	26,343
Employee Count	17,600
Asset Turnover	0.47
Inventory Turnover	3.58

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +53.45% in the last 52 weeks. The beta is 0.24, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.24
52-Week Price Change	+53.45%
50-Day Moving Average	99.71
200-Day Moving Average	82.42
Relative Strength Index (RSI)	54.37
Average Volume (20 Days)	2,485

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.60

Income Statement

In the last 12 months, Gilead Sciences had revenue of EUR 27.77 billion and earned 463.63 million in profits. Earnings per share was 0.37.

Revenue	27.77B
Gross Profit	21.74B
Operating Income	10.32B
Pretax Income	667.44M
Net Income	463.63M
EBITDA	13.00B
EBIT	10.32B
Earnings Per Share (EPS)	0.37

Full Income Statement

Balance Sheet

The company has 11.17 billion in cash and 26.39 billion in debt, giving a net cash position of -15.22 billion.

Cash & Cash Equivalents	11.17B
Total Debt	26.39B
Net Cash	-15.22B
Net Cash Per Share	n/a
Equity (Book Value)	18.59B
Book Value Per Share	14.98
Working Capital	6.92B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 10.46 billion and capital expenditures -505.17 million, giving a free cash flow of 9.95 billion.

Operating Cash Flow	10.46B
Capital Expenditures	-505.17M
Free Cash Flow	9.95B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.26%, with operating and profit margins of 37.17% and 1.67%.

Gross Margin	78.26%
Operating Margin	37.17%
Pretax Margin	2.40%
Profit Margin	1.67%
EBITDA Margin	46.79%
EBIT Margin	37.17%
FCF Margin	35.84%

Dividends & Yields

This stock pays an annual dividend of 2.87, which amounts to a dividend yield of 2.79%.

Dividend Per Share	2.87
Dividend Yield	2.79%
Dividend Growth (YoY)	2.99%
Years of Dividend Growth	10
Payout Ratio	816.25%
Buyback Yield	0.24%
Shareholder Yield	3.02%
Earnings Yield	0.36%
FCF Yield	7.74%

Dividend Details

Stock Splits

The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.

Last Split Date	Jan 28, 2013
Split Type	Forward
Split Ratio	2

Scores

Gilead Sciences has an Altman Z-Score of 2.96. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.96
Piotroski F-Score	n/a